$BLUE (bluebird bio, Inc.)

$BLUE {{ '2017-06-05T16:32:59+0000' | timeago}} • Announcement

$BLUE and $CELG said updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell therapy, in 18 patients with relapsed/refractory multiple myeloma will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

$SGMO {{ '2017-10-02T16:06:18+0000' | timeago}} • Announcement

$SGMO and $BIVV said the FDA has accepted the Investigational New Drug (IND) application for ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia. $SGMO expects to open several clinical sites across the United States and begin enrolling patients in 1H18.

$SGMO {{ '2017-10-02T16:05:15+0000' | timeago}} • Announcement

$SGMO and $BIVV said the FDA has accepted the Investigational New Drug (IND) application for ST-400, a gene-edited cell therapy candidate for people with transfusion-dependent beta-thalassemia. This is as part of exclusive worldwide collaboration to develop and commercialize gene-edited cell therapies for beta-thalassemia and sickle cell disease.

$BIIB {{ '2017-09-25T14:11:23+0000' | timeago}} • Announcement

$BIIB appointed Camille Lee as Senior Vice President, Alzheimer’s Therapeutic Area, effective immediately. In this new role, she will report directly to Chief Medical Officer Alfred Sandrock, Jr., M.D., Ph.D. and will be based in Cambridge.

$BIIB {{ '2017-09-12T12:31:48+0000' | timeago}} • Announcement

$BIIB named Sanjay Jariwala as SVP, Worldwide Medical. Jariwala will be responsible for leading and driving $BIIB's Worldwide Medical strategy working closely with the company’s global therapeutic operations and R&D leadership teams. He will be based in Cambridge, Massachusetts, and report directly to Chief Medical Officer Alfred Sandrock, Jr.

$ABBV {{ '2017-09-06T15:45:07+0000' | timeago}} • Announcement

$ABBV, in cooperation with $NBIX, has submitted a New Drug Application to the FDA for elagolix, an investigational, orally administered gonadotropin-releasing hormone antagonist, being evaluated for the management of endometriosis with associated pain. The pain includes daily menstrual pelvic pain, non-menstrual pelvic pain and painful intercourse.

$BIIB {{ '2017-07-31T14:52:32+0000' | timeago}} • Announcement

$BIIB named Anabella Villalobos as SVP, Biotherapeutic & Medicinal Sciences. Villalobos will lead the company's Biotherapeutic & Medicinal Sciences organization in the delivery of high-quality, differentiated molecules to the clinic. She will report to Michael Ehlers, EVP, Head of Research and Development.

$BIIB {{ '2017-07-26T13:59:55+0000' | timeago}} • Webcast

In multiple sclerosis, $BIIB's 2Q17 global TECFIDERA revenue growth was driven by volume growth, while patient growth in TECFIDERA was driven by its newly launched markets such as Italy, Poland & Japan. For FY17 ex-US, $BIIB expects SPINRAZA revenues to be modest, mainly from Germany and Japan. However, patient intake in the US is expected to grow.

$BIIB {{ '2017-07-26T13:46:38+0000' | timeago}} • Webcast

$BIIB's priority for capital deployment going forward is to invest in building its pipeline across its core growth areas like Alzheimer's, Parkinson's and neuromuscular disease and emerging areas like pain, ophthalmology and neuropsychiatry. $BIIB expects to have about $400MM available by 2019 for R&D and commercial value creation opportunities.

$BIIB {{ '2017-07-25T15:15:33+0000' | timeago}} • Announcement

$BIIB named Alisha Alaimo as SVP of US Therapeutic Operations. In this position, Alaimo will lead $BIIB's sales and marketing, market access, patient services and commercial operations and strategy. Alaimo will join the company from $NVS, where she was VP and Head of its Cardiovascular Business Unit.

$BIIB {{ '2017-07-25T15:07:04+0000' | timeago}} • Announcement

On a segment basis, $BIIB's revenue for TECFIDERA, PLEGRIDY and FAMPYRA increased YoY in 2Q17, while total Total Interferon and AVONEX reported decline in revenues. In other products, Biosimilars revenue surged significantly to $91MM in the quarter from $15MM a year ago.

$BIIB {{ '2017-07-25T14:59:43+0000' | timeago}} • Announcement

Drugmaker $BIIB increased its revenue outlook for FY17 to $11.5-11.8Bil, due to faster than expected adoption of SPINRAZA in the US. GAAP diluted EPS guidance was narrowed to $17.05-17.65 from the earlier guidance of $18-18.80. Adjusted EPS guidance, however, was raised to $20.80-21.40 from the prior guidance of $20.45-21.25.

$BIIB {{ '2017-07-25T14:47:25+0000' | timeago}} • Announcement

$BIIB, which competes with $ABT and $PFE, posted record 2Q17 revenue, on strong Spinraza demand in the US, though YoY profit fell 18% on higher expenses. Net earnings attributable to Biogen plunged to $862.8MM, while diluted EPS fell 15.03% to $4.07. Revenue, however, jumped 6% to $3.1Bil. $BIIB lifted its outlook due to strong Spinraza sales.

$BIIB {{ '2017-07-25T12:18:23+0000' | timeago}} • Announcement

$BIIB Biogen Inc. Earnings AlphaGraphic: Q2 2017 Highlights

$BIIB {{ '2017-07-10T12:58:24+0000' | timeago}} • Announcement

$BIIB appointed Amy Chevalier Efantis as VP of Government Affairs, effective July 17. Efantis brings more than two decades of legislative, public policy, and advocacy experience in the biopharma industry and the public sector. She will lead the company's federal and state government affairs activities from $BIIB's Washington, D.C., office.

$BIIB {{ '2017-06-28T12:10:03+0000' | timeago}} • Announcement

Pharma company $BIIB has appointed Catherine Steele as SVP of Corporate Affairs, effective July 17, 2007. Most recently, Steele served Novartis Pharmaceuticals as Global Head of Communications and Patient Relations. She began her biopharma career with Roche, where she worked more than a decade.

$RGEN {{ '2017-06-23T12:45:15+0000' | timeago}} • Announcement

$RGEN entered into a definitive merger agreement with privately-held Spectrum, Inc. for about $359MM, comprised of $120MM in cash and 6.2MM shares of Repligen stock. The transaction is expected to be completed during 3Q17.

$BIIB {{ '2017-06-14T14:06:09+0000' | timeago}} • Announcement

$BIIB appointed Jean-Paul Kress as EVP and President, International, and Head of Global Therapeutic Operations, effective June 19, 2017. Kress will have direct responsibility for worldwide commercial operations outside the US and will also oversee the Rare and Specialty Disease Asset teams.

$BIIB {{ '2017-06-13T21:38:43+0000' | timeago}} • Announcement

$BIIB said Paul Clancy, EVP, Finance & CFO will leave the organization to join another biopharmaceutical company. Clancy will remain at the company through 2Q and assist with the transition. CAO Greg Covino will serve as the company's interim Principal Financial Officer as the company conducts a search for a new CFO.

$BLUE {{ '2017-06-05T16:32:59+0000' | timeago}} • Announcement

$BLUE and $CELG said updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-BCMA CAR T cell therapy, in 18 patients with relapsed/refractory multiple myeloma will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois.

$BIIB {{ '2017-05-15T13:05:04+0000' | timeago}} • Announcement

$BIIB closed asset purchase of Remedy Pharmaceuticals' Phase 3 candidate, Cirara. $BIIB plans to continue development and commercialization of Cirara. Remedy will share in cost of development for target indication for Cirara in LHI stroke. $BIIB will make $120MM upfront payment to Remedy and may also pay additional milestone payments and royalties.

Recent Transcripts

PTN (Palatin Technologies Inc.)
Monday, September 25 2017 - 3:00pm
HEB (Hemispherx Biopharma, Inc.)
Tuesday, August 15 2017 - 5:00pm
FATE (Fate Therapeutics, Inc.)
Monday, August 14 2017 - 9:00pm
XON (Intrexon Corporation)
Wednesday, August 9 2017 - 9:30pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, August 9 2017 - 9:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, August 9 2017 - 9:00pm
INFU (InfuSystem Holdings, Inc.)
Wednesday, August 9 2017 - 8:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, August 9 2017 - 12:00pm
VICL (Vical Incorporated)
Tuesday, August 8 2017 - 4:00pm
NBIX (Neurocrine Biosciences Inc.)
Thursday, August 3 2017 - 9:00pm
RGEN (Repligen Corporation)
Thursday, August 3 2017 - 12:31pm
QGEN (Qiagen NV)
Friday, July 28 2017 - 1:00pm
BIIB (Biogen Inc.)
Tuesday, July 25 2017 - 12:00pm
ONVO (Organovo Holdings, Inc.)
Wednesday, June 7 2017 - 9:00pm
PTN (Palatin Technologies Inc.)
Tuesday, May 16 2017 - 3:00pm
VICL (Vical Incorporated)
Monday, May 15 2017 - 4:00pm
INFU (InfuSystem Holdings, Inc.)
Friday, May 12 2017 - 1:00pm
SGMO (Sangamo Biosciences Inc.)
Wednesday, May 10 2017 - 9:00pm
XON (Intrexon Corporation)
Wednesday, May 10 2017 - 8:30pm
NAVB (Navidea Biopharmaceuticals, Inc)
Wednesday, May 10 2017 - 12:00pm

AlphaGraphics you may like